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The 13th Acromegaly Consensus Conference was held in November 2019 in Fort Lauderdale, 
Florida, and comprised acromegaly experts including endocrinologists and neurosurgeons who 
considered optimal approaches for multidisciplinary acromegaly management. Focused 
discussions reviewed techniques, results, and side effects of surgery, radiotherapy, and medical 
therapy, and how advances in technology and novel techniques have changed the way these 
modalities are used alone or in combination. Effects of treatment on patient outcomes were 
considered, along with strategies for optimizing and personalizing therapeutic approaches. 
Expert consensus recommendations emphasize how best to implement available treatment 
options as part of a multidisciplinary approach at Pituitary Tumor Centers of Excellence. 
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Acromegaly is a chronic, progressive, and potentially lethal disease caused by a growth hormone 
(GH)-secreting pituitary adenoma and resultant excess in circulating levels of GH and insulin-
like growth factor (IGF)-I (1). Facial and acral changes due to soft tissue overgrowth as well as 
systemic complications affecting bone and joints (2) and the cardio-respiratory system (3), in 
association with metabolic and oncologic complications, contribute to an increased clinical 
burden, leading to decreased quality of life and diminished survival rates (4, 5). Unfortunately, 
most patients already exhibit features of advanced disease at presentation due to a delay in diagnosis 
from first symptom onset by up to 8-10 years (6). Treatment of acromegaly is targeted to 
normalizing biochemical parameters as well as improving well being, controlling signs and 
symptoms, and reducing excess morbidity and mortality (7, 8). A multimodal therapeutic 
approach comprising neurosurgery, medical therapy, and radiotherapy is often required to attain 
these goals (9). Therefore, a multidisciplinary team approach is recommended for effective 
management of acromegaly and its comorbidities, coordinated by pituitary medicine experts to 
personalize treatment and follow-up, and optimize outcomes (10). 
In November 2019, the Acromegaly Consensus Group convened in Fort Lauderdale, 
Florida, to provide current consensus on the comprehensive multidisciplinary management of 
acromegaly. Forty-eight acromegaly experts including endocrinologists and neurosurgeons 
reviewed the current literature and assessed current treatment choices and prioritization for 
clinical practice. Discussions focused on treatment outcome goals; results and side effects of 
neurosurgery, radiotherapy, and medical therapy; and the proposed place of each available 
treatment option in the guidelines. Updated consensus recommendations on treatment of patients 
with acromegaly were graded using the Grading of Recommendations Assessment, Development 
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and Evaluation (GRADE) system (11). Key recommendations are presented in Table 1 and 
outlined in Figure 1. 
 
Methods 
Literature searches were performed by meeting participants to identify new data in 
English language papers published between January 2014 and October 2019, and indexed in 
PubMed. Search terms included “acromegaly” and terms associated with each topic, including 
“biochemical control”, “tumor volume”, “clinical symptoms”, “side effects”, “neurosurgery”, 
“radiotherapy”, “somatostatin analogue”, “somatostatin receptor ligand”, “pegvisomant”, 
“morbidity”, “mortality”, “quality of life”, and “guidelines”. After brief plenary overviews on the 
state of the art for each topic, participants were divided into breakout groups for further analysis 
of the assigned topics and subsequently reported their conclusions to the whole group. 
Consensus recommendations were produced based on speaker presentations, subgroup 
discussions, and reports. After the meeting, the Scientific Committee graded the evidence 
supporting the recommendations, and then graded the consensus recommendations on the basis 
of the quality of evidence (Table 2). Final graded consensus recommendations were approved by 
all meeting participants. 
 
Targets for Therapeutic Approaches 
GH and IGF-I 
Excess GH and/or IGF-I lead to systemic comorbidities in patients with acromegaly, requiring 
effective treatment to decrease disease burden and reduce or normalize excess mortality (HQ) 
(12). Although consideration of tumor and clinical variables is important for clinical 
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management, biochemical control is the cornerstone on which succesful treatment is built .Thus, 
at present, normalization of GH and IGF-1 is still the primary goal of acromegaly treatment and 
biochemical parameters should be used to evaluate activity of disease (SR).  
GH nadir <1 μg/L after an oral glucose tolerance test (OGTT) was initially defined by our 
Consensus Group as a marker of postsurgical remission (13); subsequently, this recommendation 
was revised to 0.4 μg/L taking into account use of ultrasensitive GH assays (14). However, GH 
nadir levels during an OGTT are impacted by factors such as patient age, BMI, sex, and estrogen 
status (15) (LQ), as well as glucose intolerance and diabetes mellitus or preexisting use of 
antidiabetic and somatostatin receptor ligand (SRL) therapy (VLQ) (16). Nevertheless, as these 
cutpoints correlate well with long-term outcomes (17), we recommend that ultrasensitive assays 
be used for diagnosis, and post-surgical evaluation using the 0.4 µg/L threshold for cut-off (SR). 
During follow-up, IGF-I levels reflect clinical activity of disease (MQ) (1). However, 
wide variability between assays has been reported due to several preanalytical and analytical 
confounding factors (MQ) (18), and fluctuation of circulating IGF-I levels may be seen, 
particularly in the early postoperative period or after treatment changes (MQ) (19). It is therefore 
recommended that the same well-validated IGF-I assay be used throughout patient follow-up 
(SR). Further, although the absolute cut-off for defining biochemical control is the upper limit of 
normal (ULN) (SR), values slightly higher than this cut-off (e.g., within 1.2-1.3 × ULN) could be 
considered as a target of treatment depending on the clinical scenario (20, 21) (DR). Serum GH 
values can be used to assess control, with the goal of achieving a fasting level <1.0 µg/L. Close 
follow-up is recommended for patients with discrepant GH and IGF-1 levels observed at 3 
months postoperatively; most commonly, patients show controlled GH and elevated IGF-I, but 
10 




Tumor growth control, and ideally, decreasing tumor size, are clinically important goals for 
patients with acromegaly (SR) (4). We recommend to continue evaluating reduction in mass 
maximal dimension, rather than overall tumor volume, which is not standardized (24) (DR). As 
the latter is a better measure of response, a consensus on methodology for measuring tumor 
volume would be welcomed by the physician community. 
T2-weighted MRI hypointensity may be helpful for predicting SRL therapy responsiveness 
(MQ) (25-27), along with adenoma granularity and other histological markers (VLQ) (7), but are 
not currently validated for guiding treatment. Tumor characteristics, such as the degree of 
adenoma fibrosis and  consistency may be evaluated by texture analysis which is currently 
restricted to clinical trial settings to evaluate clinical precision. 
 
Clinical Symptoms 
As symptoms and comorbidities associated with acromegaly impact quality of life and 
survival, their prevention and control is a major goal of treatment (SR) (4). We recommend 
assessing and aggressively managing disease-associated comorbidities (SR). However, 
symptoms and clinical manifestations can be dissociated from biochemical values (LQ) (28), and 
specific assessment and clinical monitoring is recommended beyond biochemical parameters 
(SR).  
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Clinician-reported instruments such as SAGIT (Signs and symptoms, Associated 
comorbidities, GH levels, IGF1 levels and Tumour profile) (29) and ACRODAT (Acromegaly 
Disease Activity Tool) (30) as well as patient-reported outcome assessment measures have been 
proposed to standardize follow-up over time (VLQ) (31-33), and their use can be considered in 




Tumor resection via transsphenoidal surgery is the optimal primary treatment in most patients 
(HQ) (34) (Figure 1). Data supporting use of endoscopic over microscopic approaches remain 
incomplete and further comparative outcome studies are needed before one approach can be 
recommended over the other. Currently, the choice of technique depends on neurosurgeon 
expertise and preference. Craniotomy is very rarely indicated in patients with acromegaly (HQ) 
(35). Intraoperative MRI and other techniques to aid in intraoperative visualization of tumor 
remnants remain investigational (LQ) (36, 37). 
 
Results 
The primary predictor of the likelihood of achieving surgical remission remains tumor size and 
invasiveness of surrounding structures, particularly the cavernous sinus (HQ) (38, 39). Knosp 
grading may be correlated to outcomes (40). Preoperative serum GH level is also an important 
determinant of surgical remission (41, 42).   
In specialized referral centers, remission can be achieved in 80-90% of microadenomas 
and about 50% to 75% of macroadenomas, although these figures dramatically decrease when 
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the tumor is invasive or very large (e.g., >4 cm). (HQ) (43, 44). Remission rates are likely lower 
at less experienced centers 
Surgical tumor debulking prior to medical therapy can be considered in appropriate 
candidates if the patient cannot be surgically cured (MQ), if a substantial amount of the mass can 
be successfully removed and/or there are symptoms of mass effect (45). Debulking may also be 
appropriate prior to radiotherapy to decrease target volume (DR). 
Serum IGF-I levels to reliably define remission should be assessed at least 3 months 
postoperatively (HQ) (43, 44). Early indication of remission may be obtained by measuring 
fasting GH on postoperative day 1 or 2, with lowest levels (<1 µg/L) having the best sensitivity 
to predict outcomes. However, these data need to be interpreted with caution if patients are 
treated with preoperative SRL therapy (VLQ) (43). 
Expertise in surgical management of acromegaly, together with initial tumor dimension, 
has a dramatic impact on disease control rates (HQ) (10). A high volume of pituitary operations 
per individual surgeon per year with monitoring of outcome data is recommended to maintain 
sufficient surgical expertise (DR) (46). 
 
Preoperative SRL therapy 
Randomized studies suggest improvement in postoperative remission after pretreatment with 
SRL for 3-6 months (MQ). However, data are conflicting and, in many instances, results were 
not sustained during long-term follow-up (LQ) (47-50). The role of SRL pretreatment in 
improving anesthetic risk is not clear and current data do not support a general recommendation 




Reoperation may be considered in patients with significant residual tumor who have not 
adequately responded to postoperative SRL or in patients with a potentially resectable residual 
tumor after an unsuccessful first surgery (LQ) (52). Reoperation, as for primary surgery, should 
be done in a specialized center and after multidisciplinary evaluation (53) (SR). 
 
Complications 
Surgical complications after transsphenoidal surgery are well-recognized, although they occur 
less commonly with experienced surgeons (46). Post-surgical hypopituitarism can occur in 5-
10% of cases and persistent CSF leakage in 2-3%. (54) Other serious complications (e.g., visual 
deterioration, carotid artery injury, transient oculomotor palsies, and meningitis) are rarely 
observed (MQ) (55-57). Diabetes insipidus occurs at a rate similar to surgically treated pituitary 
tumors (10-15%), and is usually transient. The syndrome of inappropriate antidiuretic hormone 
secretion may occur 5-14 days after surgery and requires vigilance, with frequent monitoring of 
serum sodium levels and possibly fluid restriction (LQ) (58, 59).  
Advanced age, severe cardiomiopathy, and poorly controlled diabetes mellitus are 




Modern radiotherapy continues to have a place in the treatment algorithm, typically as a third-
line option after surgery and optimal medical therapy. There are two indications for radiotherapy: 
control of tumour growth and/or lowering GH secretion (60) (MQ). The earlier era of 
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conventional radiotherapy was associated with complications, particularly cerebrovascular 
disease and secondary tumours, as well as hypopituitarism (9) (MQ). Modern stereotactic 
radiotherapy techniques are localised accurately in 3-dimensions, and are delivered either as a 
single fraction or fractionated. The relatively small number of patients undergoing pituitary 
radiotherapy and the long latency for an observed effect make it difficult to draw definitive 
conclusions about complication rates. However, single-fraction stereotactic radiosurgery appears 
to be associated with similar but fewer side effects as compared to fractionated radiotherapy 
(LQ) (60-65).  
Radiation therapy should be administered in specialized centers where patient selection is 
guided by discussion within a multidisciplinary team, and treatment should be delivered by 
radiotherapists experienced in treating pituitary disease to both maximize efficacy and prevent 
long-term complications (SR).  
 
Results 
Radiotherapy is reserved for patients that have failed, are unfit for, or declined surgical 
and/or medical therapy (SR) (Figure 1), and may be considered as second-line treatment in select 
patients (VLQ). Radiotherapy can control biochemical parameters in more than 60% of patients, 
and is highly efficacious (>90%) in controlling tumor growth, offering the prospect of stopping 
high-cost lifelong medical therapy (MQ). However, full response may not be realized until up to 
10-15 years after administration (MQ) (60-66). Given the delay in suppressing GH and IGF-I 
levels, medical therapy is indicated in the intervening years (SR).  
 
Side Effects and Contraindications 
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Safety is the main limiting factor for use of radiation therapy in acromegaly, especially as safety 
of other treatment modalities has improved. There are currently no comparative studies of side 
effects caused by different modalities of radiotherapy. Reduced incidence of non-endocrine 
complications (i.e., secondary tumors, cerebrovascular disease, optic neuritis, cranial nerve 
palsy) may be observed with more focused techniques (LQ) (60-65). Hypopituitarism is the most 
frequent complication, regardless of technique, and increases over time, with rates approaching 
25-50% after 5 years (MQ) (67). Routine monitoring of endocrine function should be conducted 
lifelong (SR).  
 
Medical Therapy 
Medical therapy is recommended for patients who do not achieve biochemical control after 
surgery (SR). Primary medical therapy is reserved for those with contraindication to or who 
refuse surgery, and may be considered in select patients considered at poor risk for good 
outcomes and surgical success (DR) (68) (Figure 1). 
 
SRL 
Octreotide LAR and lanreotide are used as first-line medical therapy due to their favorable 
risk/benefit profiles (SR). Thirty to 55% of patients achieve normal IGF-I on long-term treatment 
with these SRLs (MQ) (68-72) and >20% reduction in tumor size is seen in more than half of 
treated patients (MQ) (73, 74). Lower baseline IGF-I level and older age are strong predictors of 
response (MQ) (75-77). Increasing dose and/or dose frequency of octreotide LAR and lanreotide 
can improve biochemical control rates in patients inadequately controlled on standard doses, but 
sensitive to SRL therapy (LQ) (78, 79). An oral formulation of octreotide was recently approved 
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in the United States as long-term maintenance treatment in patients who have responded to and 
tolerated treatment with octreotide or lanreotide (80). Pasireotide LAR can be effective in 
normalizing IGF-1 levels in some patients inadequately controlled by octreotide LAR or 
lanreotide (MQ) (81-83), and may yield a higher rate of tumor shrinkage (LQ) (82). 
Side effects of SRL include mainly gallstones and GI symptoms (1). Long-term 
octreotide LAR and lanreotide generally have an overall neutral effect on glucose metabolism 
(MQ), although in some patients mild hyperglycemia is observed (84). By contrast, pasireotide 
LAR causes hyperglycemia in up to 70% of patients, including secondary diabetes in 25-40% of 
patients (LQ) (85). Candidates for pasireotide LAR should therefore be carefully screened and 
monitored for glycemic adverse effects (SR). Controlled studies on the best treatment of 
pasireotide-induced hyperglycemia are not available. Patients not controlled on oral antidiabetic 
medications, including metformin, could be better managed with glucagon-like peptide-1 
receptor agonists rather than insulin (DR) (86).  
 
Cabergoline 
Cabergoline, a relatively long acting dopamine agonist, has the advantages of limited cost and 
oral route of administration compared to SRL. However, its positioning in the therapeutic 
algorithm is limited by its relatively modest effect on inducing biochemical control, primarily 
restricted to patients who have mild-GH/IGF-I elevations postoperatively (IGF-I levels <2.5 x 
ULN) (7), as well as an escape phenomenon that can occur (87, 88). Some studies have 
suggested that cabergoline may be useful as add-on therapy in patients who do not achieve 




Unlike all other medical therapies, the GH receptor antagonist pegvisomant is not dependent on 
tumor characteristics for efficacy (91). Pegvisomant is generally used as second-line therapy in 
patients who do not achieve biochemical control with maximal doses of SRL (SR), although 
observational data suggest that it is  also effective when used as first-line therapy (VLQ) (92). As 
higher rates of control are often seen as the dose is increased (93-97), treatment should be started 
at low doses and uptitrated as tolerated until control can be achieved (SR). Potentially, any 
patient can be controlled with adequate dose titration (MQ), but the high cost of treatment is 
often an obstacle to adequate dose titration (98) (VLQ).Younger patients with more aggressive 
disease, higher baseline IGF-I levels, and associated comorbidities may require higher doses to 
acheive biochemical control (LQ) (97). Loss of biochemical control due to tumor regrowth, 
previous treatment modifications, concomitant menopause, and changes in testosterone 
administration, can be corrected by increasing the dose (LQ) (99, 100).  
Degree of improvement in clinical outcomes with pegvisomant is variable and is 
dependent upon the specific comorbidity and the duration of disease (101-103) (LQ). Compared 
to other forms of medical therapy, pegvisomant is the most likely to achieve maximal 
improvement in glucose tolerance and insulin sensitivity (MQ) (102, 103). Accordingly, 
pegvisomant is the preferred medical therapy for patients with preexisting hyperglycemia or 
diabetes mellitus who do not respond to octreotide LAR/lanreotide (SR). Abnormal liver 
function can occur early and should be monitored (SR) (97). Tumor size may rarely increase in 
patients switching from SRL, possibly as a rebound after stopping SRL but more likely due to 
the absence of a pituitary-targeting therapy (97, 104) (LQ). Pegvisomant is therefore preferred 
for patients with no clinically relevant residual tumor (SR). 
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Combination Pegvisomant and SRL Therapy 
Higher rates of biochemical control are seen in patients treated with combination pegvisomant 
and octreotide/lanreotide compared to those on SRL alone (MQ) (104,105), and the combination 
may be considered in patients with a concern for residual tumor control and impaired glucose 
tolerance instead of switching to pasireotide LAR (DR) (8). The combination of pegvisomant 
and pasireotide LAR is effective in achieving biochemical control with lower pegvisomant doses 
but no clear advantage has yet been shown in attenuating the hyperglycemic effects of 
pasireotide (LQ) (106, 107). Nevertheless, this combination, although costly, may be an option 
among those with observed tumor growth if radiotherapy is either contraindicated or not 
available or while awaiting tumor-shrinking effects of radiation in more aggresive tumors (DR). 
 
Temozolomide 
Use of temozolomide and other chemotherapeutic agents should be limited to patients with 
highly aggressive or truly malignant pituitary tumors (108) and should be administered under 
supervision of a neuro-oncologist (109) (DR). 
 
The Multidisciplinary Treatment Approach 
The availability of increased management options has enabled a more effective 
multimodality treatment of acromegaly, requiring a higher degree of treatment personalization. 
Treatment of acromegaly is best determined by a multidisciplinary team of experts within the 
structure of a Pituitary Tumors Center of Excellence (PTCOE), preferably in a single institution 
where feasible (SR) (9) (MQ). The PTCOE should have a sufficiently large referral population to 
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allow neurosurgeons to have post-residency training in a high-volume pituitary center, a 
continuous multidisciplinary experience, and a possibility to publish outcomes for pituitary 
tumor operations (DR) (46). Ideally, more than one surgeon per center should be available. In 
addition to experts in transsphenoidal pituitary surgery and pituitary disease endocrine 
management, the multidisciplinary team should include neuroradiologists, neuropathologists, 
radiation oncologists, and nurses with specific expertise in pituitary medicine (9) (LQ). A 
multidisciplinary treatment approach at a PTCOE where current guidelines are implemented and 
up-to-date and validated laboratory and clinical tools are routinely used offerrs the best 
opportunity for optimizing outcomes and quality of life while also ensuring that disease-
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Table 1. Key Recommendations* 
1. During follow-up, measurement of IGF-I levels with the same well-validated  assay is 
recommended. Values slightly higher than a standard cut-off for age-adjusted 
normalization (e.g.,within 1.2-1.3 × ULN) may be considered sufficient for control of 
acromegaly. 
2. Prevention and control of symptoms and comorbidities is a major goal of treatment. 
Assessing and aggressively managing disease-associated comorbidities is recommended, 
with use of clinician- and patient-reported outcome measures to help standardization of 
follow-up strategies.  
3. Tumor resection via transsphenoidal surgery (either endocscopic or microscopic) is a safe 
and effective primary treatment for most patients. The primary predictors of surgical 
remission are tumor size, invasiveness (Knosp grade), and experience of the 
neurosurgeon.  
4. Medical therapy is recommended for patients who do not achieve biochemical control 
after surgery. Choice of therapy among dopamine agonist, SRL, and GH receptor 
antagonist should be individualized based on disease- and patient-specific factors known 
to affect therapeutic efficacy and safety. 
5. Radiotherapy is reserved for patients that have failed, are unfit for, or declined surgical 
and/or medical therapy. It should be administered in specialized centers to maximize 
efficacy and minimize long-term complications 
6. Treatment of acromegaly is best determined by a multidisciplinary team of experts within 
the structure of a PTCOE, preferably in a single institution with a sufficiently large 
40 
referral population. Such an approach is more likely to optimize outcomes and quality of 
life while minimizing disease-associated morbidity and decreasing mortality. 
 
*These recommendations were selected among all the recommendations included in the text 
based on a formal vote from all authors and reflect the consensus reached within the group. 
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Table 2. Grading of Evidence and Recommendations 
Grading the evidence Grading the recommendations 
• Very low quality (VLQ): expert opinion 
supported by one or few small 
uncontrolled studies 
• Low quality (LQ): supported by large 
series of small uncontrolled studies 
• Moderate quality (MQ): supported by one 
or few large uncontrolled studies or meta-
analyses 
• High quality (HQ): supported by 
controlled studies or large series of large 
uncontrolled studies with sufficiently long 
follow-up 
• Discretionary recommendation (DR): 
based on VLQ or LQ evidence 
• Strong recommendation (SR): based on 
MQ or HQ evidence 
Adapted with permission from Melmed et al (7) 
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Figure 1. Algorithm for the Multidisciplinary Management of Acromegaly  
 
aIf curative surgery is not feasible; bConsider in cases of mild postoperative GH/IGF-I elevations. 
Well controlled defined as normalized GH/IGF-I; not controlled defined as other than well-
controlled. Abbreviations: IGF-I, insulin-like growth factor- I; SRL, somatostatin receptor ligand 
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